A patient with a Ph-positive chronic myeloid leukaemia (CML) was submitted to allogeneic peripheral blood stem cell transplantation from an HLA-haploidentical related donor 7 years after the diagnosis. Six months later, he showed a disease relapse while cytogenetic analysis displayed a complex karyotype. To characterise the chromosomal rearrangements spectral karyotype (SKY) analysis was used. This redefined all chromosome rearrangements and revealed a t(20;21)(q11;q22). FISH analysis with a specific probe for the AML1 gene disclosed disruption of this gene which was partially translocated on to the long arm of chromosome 20. It is likely that this rearrangement, unusual for CML, was implicated in the disease evolution towards blastic crisis (BC). Bone Marrow Transplantation (2000) 26, 1125-1127.
Summary:
A patient with a Ph-positive chronic myeloid leukaemia (CML) was submitted to allogeneic peripheral blood stem cell transplantation from an HLA-haploidentical related donor 7 years after the diagnosis. Six months later, he showed a disease relapse while cytogenetic analysis displayed a complex karyotype. To characterise the chromosomal rearrangements spectral karyotype (SKY) analysis was used. This redefined all chromosome rearrangements and revealed a t(20;21)(q11;q22). FISH analysis with a specific probe for the AML1 gene disclosed disruption of this gene which was partially translocated on to the long arm of chromosome 20. It is likely that this rearrangement, unusual for CML, was implicated in the disease evolution towards blastic crisis (BC). Bone Marrow Transplantation (2000) 26, 1125-1127. Keywords: Philadelphia chromosome; chimeric gene; SKY; FISH CML is a myeloproliferative disorder characterised by welldifferentiated myeloid hyperplasia during chronic phase (CP). This is probably related to the p210 chimeric protein resulting from fusion of the ABL and BCR genes as a consequence of the translocation between chromosomes 9 and 22. 1 This hybrid protein has a high tyrosine kinase activity and transforming capability. 2, 3 However, the link between the molecular and cellular phenotypes still remains poorly understood. During CP 70-80% of cases develop clonal cytogenetic abnormalities, including isochromosomes for the long arm of chromosome 17, trisomy 8, trisomy 19, and duplication of Ph chromosome, which are specifically associated with the evolution of the disease into the blastic crisis (BC). These abnormalities are considered as 'major routes' for progression. 4 In about 20-25% of patients in CP secondary changes do appear, which are regarded as 'minor routes'. [4] [5] [6] They include t(3;21)(q26;q22), monosomy 7 and monosomy 17, trisomy 17 and trisomy 21, and loss of the Y chromosome. The prognostic significance of these abnormalities is unknown although they are associated with the leukaemia phenotype. In fact, the t(3;21) is seen only in myeloid malignancies 7 and the appearance of t(8;21)(q22;q22), t(15;17)(q22;q11-q21), inv(16)(p13;q22) transform the disorder into a distinct malignancy. 8, 9 These minor routes have been associated with different treatments such as intensive chemotherapy, bone marrow transplantation (BMT), busulfan and interferon-alfa (IFN-alfa). 5, 6, 10, 11 We report a case of Ph-positive CML that, after allogeneic peripheral blood stem cell transplantation, developed a complex karyotype in which a t(20;21)(q12;q22) associated with the Ph chromosome and an indecipherable marker was detected during myeloid transformation.
Materials and methods

Case report
A 37-year-old man was referred to the Haematology Department in July 1992, because of leukocytosis. Clinical and laboratory results suggested the diagnosis of CML in CP. The patient was continuously treated with hydroxyurea maintaining the dosage between 0.5 and 2 g/day, in order to obtain a normal leukocyte count. In October 1998, he presented with symptoms of accelerated phase (AP) of the disease, and consequently underwent a splenectomy. In May 1999, he received peripheral blood stem cell transplantation from an HLA-haploidentical related donor. The conditioning regimen consisted of total body irradiation (12 Gy for 3 days), fludarabine (200 mg/m 2 ) and anti-thymocyte globulin (ATG). Prophylaxis administration for graft-versus-host disease (GVHD) was performed with cyclosporin A (CsA). In December 1999, the patient showed a myeloid BC with an abdominal skin localisation of the disease documented by biopsy. The patient in this phase was unsuccessfully treated with high doses of cytosine arabinoside and mitoxantrone. After 3 months, the patient died due to disease progression.
Bone Marrow Transplantation
Standard cytogenetic analysis
Cytogenetic investigation was carried out on unstimulated bone marrow cells incubated for 24 h. Metaphase chromosomes were GTG banded and 16 metaphases were analysed.
Spectral karyotyping (SKY) and classical fluorescence in situ hybridisation (FISH) analyses
SKY experiments were performed according to Schrock et al 12 on slides aged 8-15 days at room temperature, and 10 metaphases were used for spectral analysis.
FISH analysis was performed according to Calabrese et al 13 
Results and discussion
At diagnosis the patient had CML with the Ph chromosome as the sole abnormality. He remained in CP for 7 years and was treated during the disease course with hydroxyurea. Afterwards, an increase of leukocytes appeared and a diagnosis of an accelerated phase (AP) was established. A few months later the patient was transplanted with allogeneic peripheral stem cells from an HLA-haploidentical donor. During haematological monitoring 6 months after BMT, cytogenetic investigation disclosed the reappearance of the Ph-positive clone associated with an apparent deletion of the short arm of chromosome 6, a likely translocation affecting chromosome 21 and an indecipherable marker. On the basis of these cytogenetic results, the patient's karyotype was defined as 46,XX,-6,t(9;22) (q34;q11),add (21)(q22),+mar. In order to investigate further undefined and complex rearrangements, SKY analysis was carried out which confirmed the presence of the Ph chromosome from the standard t(9;22) and revealed der(21) as t (20;21) . This study also excluded chromosome 6 monosomy and disclosed the presence of an undetected t(1;8)(q21;q10). SKY analysis showed that the chromosome marker consisted of a complex rearrangement with chromosome 1 material in both the p arm (as an insertion) and q arm (as a translocation) of a chromosome 8 which likely resulted in partial duplication of segments of chromosome 1. The (Figure 1) . Painting probes for chromosomes 1 and 8 confirmed SKY results. Chromosome 8 anomalies, mostly trisomy 8, often occur in CML and are associated with disease progression to BC, probably as a consequence of the amplification of oncogenes, such as MYC.
14, 15 We performed FISH analysis of the MYC gene, since both chromosomes 8 were rearranged. FISH disclosed the presence of two copies of MYC, although one was translocated on to the long arm of chromosome 1 and the other on to the der(8) carrying chromosome 1 insertions (Figure 2a) . Therefore, the MYC gene appeared not to be rearranged by FISH. However, we cannot exclude chromosome 8 changes involving other genes which were implicated in the evolution of the disease in the present case. 16 SKY also disclosed a rearrangement on chromosome 1q21. This band is frequently involved in translocations or deletions in different haematological disorders, although its prognostic significance is not yet established. 17 The patient also had a t(20;21) with breaks at bands q11 and q22, respectively. The band 21q22 is frequently affected in acute myeloid leukaemia (AML). Usually a reciprocal translocation between chromosomes 8 and 21 occurs in AML type M2 (AML-M2) and a fusion gene is commonly found in the der(8) involving the AML1 gene mapped at 21q22 and the ETO gene at 8q22 (18) . A chimeric gene, involving AML1 is also found in the 3;21 translocation of patients affected by acute and chronic myeloid leukemia. 18, 19 In the present case, AML1 was disrupted as shown by FISH analysis and was partially translocated on to 20q (Figure 2b ). To our knowledge this is the first case of disruption of AML1 subsequent to a t(20;21) in haematological malignancies and mostly in CML. Translocation t(20;21) is unusual in Ph-positive CML patients as well as the disruption of the AML1 gene. It is likely that this translocation is implicated in the evolution of the disease into BC. The AML1 gene is involved in the maturation of myeloid and lymphoid cells. 18, 19 Thus, AML1 disruption could be related both with its loss of function and of the wild type through a dominant negative effect. 20 Moreover, AML1 has been shown to be involved with different translocation partners. 19 This could also be the case in the present patient in which the disrupted portion of AML1 was translocated on 20q11 and possibly fused with an hypothetical gene mapped at 20q11, with expression of a chim- eric protein, as in the translocation 3;21 in CML patients in BC. 18, 19 In addition, a fusion product involving a gene at 20q11 has been recently identified in patients with myelodysplastic syndrome. 21 This case confirms the value of SKY analysis in the precise definition of the karyotype that is crucial to the understanding of the genesis and the evolution of the disease.
